Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I thought there were more shares than that fully diluted and the reason why many got “locked up” was to prevent the company from going over their 1.2 billion share allotment.
Last time I dug into it, came out with approx 1.45 billion fully diluted and with all those shares locked up, warrant exercise could still take them to around 1.15 billion?
Maybe I’m off base— hopefully someone knows better than I.
This tells the story
Love it
Nonsensical assertions
That they would go bankrupt haha
Agree with you there. Was an early investor in TSLA and even earlier on NWBO.
TSLA received the same smear and distort campaign until it blew the shorts out of the water and they lost billions. Let’s see if it happens with NWBO. Exciting times ahead
Fantastic. Let’s get some revenue rolling in
Wow. Just watched the video too. Talk about information entropy..
I’ll venture a guess and say $22.50. Good luck and happy new year longs
Cofer is coming
Agreed 110% — in it for the long haul
Some of these warrants must have been from the toxic financiers of the past. Better they sell now than after TLD.. I guess.
Well said..
Take for example the price action of CLDX back in the day. And all Adam Feuerstein’s cheerleading for that company leading up to its trial failure.
Also NVCR massive pump in recent years despite questionable data and lackluster sales. This likely to help large players exit the stock without decimating price. Interesting to see the price decimation of NVCR happening rapidly now though, down well over 10 billion in MC in past few months. Wonder where that 10+ billion is headed? Money flowing out of oncology entirely or reallocated to somewhere else in the space?
Someone always knows and usually price is manipulated to influence retail to behave a certain way before before large players make their move.
We are all Linda’s prisoners..
How much longer does the share price stay above 1$ if the company doesn’t release any news and keeps cashing in 2-5 MILLION warrants every week?
Interesting. Thank you flipp
Agreed. Today’s price action was a surprise. Guess everyone savvy enough to understand is already bought in.
How about your capital investment company buys it, reads it, and reports to the board?????
That journal article is a very big deal. Puts to rest any remaining whining and crying about NWBO’s SAP and new primary endpoint.
Absolutely right.
They paid cognate primarily in shares MANY OF WHICH WERE GIVEN BACK TO THEM. But you already know this you clown.
And to those who think NWBO should still own Advent or that Linda is double dipping by having a part in both the drug and Manufacturing..
Who do you think is paying the 30+ Advent employees over the past couple years. They certainly haven’t been working for free. Toucan!! Would you rather NWBO pay for it?
Or would you rather NWBO contract out a big pharma to manufacture their drug? Both of these roads lead to much higher capital expenditure for NWBO.
NWBO also has a conflicts committee which oversees every single financial transaction to determine if there are any conflicts of interest. So if you think Linda is getting away with something you are clearly delusional.
If you still don’t understand, CALL DAVE INNES.
Marz, LP is not going to merge NWBO into Advent. There are many benefits to having a local manufacturing company based in the UK instead of an NWBO subsidiary.
When the MHRA gives the stamp of approval to Advent, it will be specific to that particular location, and specific to the manufacturing process for DC-Vax-L. When they manufacture Direct, that will be a separate approval. When they fully integrate flaskworks (which doesn’t need clean rooms) that will require a separate approval as well.
Flaskworks will reduce the costs to manufacture DC-Vax and once integrated into Advent, they can then use it as a bargaining chip while negotiating with other manufacturers by licensing it out.
So I don’t understand what the issue is here. NWBO owns Sawston, they own flaskworks, and the equipment. Advent is the personnel. Linda is single handedly building out manufacturing at the same time she is getting L trial to an international journal. I don’t see any better way to do it.
NWBO will be able to manufacture DC-Vax for 45-50 patients per month once ADVENT gets the stamp of approval. They will then be able to make revenue through UK specials. And then once flaskworks integration gets approved possibly around the same time as L approval in UK, they should be able to scale up to 10x capacity.
Just wait it out!
What? The chart you linked is much more scaled in than mine. I’m looking at MACD potentially crossing on weekly and flag similarities trending toward a substantial move in coming week or so.
Finally!
Me I want more at 1.05. Let’s keep pushing the no TLD till 2022 narrative. Actually how about ASCO 2023?
Approval won’t take very long in UK if they have positive data pr and manufacturing capacity of 45/month ($$$) set with future scale up with flaskworks, share price spike and favorable equity raise, major journal publication and then boom here comes a whole slew of trials, partnership, pr campaign etc.
They are not losing any time right now since development of manufacturing would still be ongoing REGARDLESS of TLD or not. That will all change very soon.
They will be silent until the time is right to be loud. And loud they will be.
True, so why not wait another year, get manufacturing up to speed, secure more patents, wait for WHO reclassification, etc..
Yup. Revenues from L to fund future Direct trials. Will be nice for loans and financings to be a thing of the past, as well as OTC dwelling.
Yes correct. She did not promote Dc-Vax or any trial specifically. This wouldn’t have been the correct forum for such statements. But she did make it clear to preserve the tumors (for vaccine clinical trials).
But if the trials we know about are already full or completed, perhaps there is another trial we don’t yet know about? Or maybe soon freezing of tumor for personalized vaccine will be SOC, and she can’t use that as reasoning for freezing the tumors, quite yet.
I’m watching it. Q&a just finished.
In the q&a someone asked why Linda Liau recommends preserving the tumors post-surgery.
And I’m paraphrasing here but Linda did say that in order to be eligible for dendritic cell vaccine trials you will need to have a sample of the tumor preserved, otherwise you will not be eligible. She recommended preserving as much of the tumor as possible as best practice because it can give you a better range of treatment options moving forward.
“On October 5, 2020, the Company announced that Data Lock for the Phase III trial had been reached, and that a series of steps and processes would follow. These processes included data validation, analyses of the data by independent statisticians, preparations by the statisticians of summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and independent experts, in preparation for publication in a scientific journal and public announcement. This series of processes is under way. It is anticipated that public announcement will follow these processes.”
Seems like they’re planning on pr and journal coming out simultaneously.. or close to it.
My NWBO popcorn went stale in 2015 :(
Completely agree.
Cheerleading and equity placement from CVM
Dead silence and 10m+ loan from NWBO.....
NICE FIND
I think I bought some of your shares